Home Contact Center Add this

Debiopharm Innovation Fund S.A.

Debiopharm Innovation Fund invests in future patient care

Debiopharm Innovation Fund1 is the strategic investment fund of the Debiopharm Group.

We invest in young innovative companies in the following areas:

  • Smart data (pilot or early commercial stage)
  • Therapeutics (discovery and early development)
  • Diagnostics (development stage) 

with a focus on technologies related to Debiopharm Group’s therapeutic areas of interest, oncology and infectious disease.

If you have an investment opportunity that falls into one of these areas, please contact us.

 

1Debiopharm Innovation Fund is the new name for Debiopharm Diagnostics from 2017

 

Our mission

Debiopharm Innovation Fund’s objective is to make strategic investments in innovative companies with technologies and business models that change the way we develop drugs and treat patients.

We bring value to our portfolio companies through our knowledge in medicine, pharmaceutical development, regulatory/reimbursement aspects, management and expertise in bringing products to market. We drive our portfolio investments to successful exits.

 

Our objective

Make new investments in companies developing innovative therapeutics, diagnostics, and smart data solutions with a spirit of partnership.
Our goals are:

  • Long term value creation
  • Minority participation
  • Advising and helping with technical and business operations
  • Active in the Board of Directors

Our investment criteria

  • Experienced management team
  • Innovative technology
  • Fit with Debiopharm Group’s interests
  • Strong execution plan

Our achievements (as Debiopharm Diagnostics)

  • Over USD 95 million invested since 2008
  • Cumulative equity raised by all companies: USD 500 million
  • Debiopharm Diagnostics led 10 out of the 14 last investment rounds
  • Progress to date: 4 companies with commercial products, one M&A and one IPO.

 

Debiopharm Innovation Fund aims at completing into two to three investments per year, with a participation in each company not to exceed 25%, and with representation on the Board of Directors.

 

CompanyDescriptionStage
Agendia

Signatures to guide cancer treatment

Prognostic tests for cancer severity and recurrence

On the market since 2004 (Europe) and 2008 (USA)

Biocartis

Point of care turn-key Dx platforms

Instruments and cartridges for simple and rapid molecular diagnostics

Idylla platform and first test launched in September 2014
Successful IPO in April 2015

Diagnoplex

Blood-based Colorectal Cancer screening

Signature for colorectal cancer used to determine the need for coloscopy

Market entry in Switzerland through collaboration with Novigenix in 2014

Eclosion

Life science platform helps translate breakthrough science into drugs by providing an incubator and resources for young biotechs

4 portfolio companies, three in clinical stage, one IPO. One merger with a public company
OSE LOGO Horizontal RVB

Fusion of Effimune and the Euronext listed OSE Pharma. Immunomodulation in autoimmunity,  transplantation, and immuno-oncology

2 clinical stage programs, several preclinical programs

Immunexpress

Potential life-saving detection of sepsis

Host response signature for early identification of sepsis

FDA clearance for the use of SeptiCyte™ LAB

Neovacs

Focused on active immunotherapy for autoimmune and inflammatory diseases

Initial public offering (IPO) in 2010

Current vaccine development efforts are in Crohn’s disease, rheumatoid arthritis and lupus. In Phase IIb/III

logo-spinomix

New solutions for MDx pretreatment

Sample preparation technologies for molecular diagnostics

Development phase of magnetic bead handling technology

Thierry Mauvernay

Thierry Mauvernay

Co-President & Delegate of the Board, Debiopharm Group™

Mr Mauvernay received his Master of Science in Economics in 1975. He then obtained a degree (MBA) from the 'Institut d'Administration des Entreprises’ and a DESS in Marketing (Master II Degree) in Clermont-Ferrand, France in 1976. In 1978, he founded an international cosmetics company, which he sold in 1998 but continued to manage until July 2001, when he joined Debiopharm International SA as Executive Vice President with direct responsibilities for the Finance and Administration Department. In 2006, Mr Mauvernay handed over his operational activities within Debiopharm International SA and has since been focusing on the administration, finance and strategy of Debiopharm Group. Since 2012, Mr Mauvernay is the Delegate of the Board of Debiopharm Group.

Tanja Dowe

Tanja Dowe

Head of Debiopharm Innovation Fund S.A.

Mrs. Dowe graduated from the Helsinki University of Technology (now Aalto University) where she obtained an MSc in Microbiology & Biochemistry in 2000. Tanja has always been interested in diagnostic and smart data solutions for precisions medicines. She has held several managing positions and has 18 years of experience in building business strategies, analyzing markets, in-/out-licensing and business acquisitions with more than 80 life sciences companies. She has strong knowledge in business models and market requirements necessary to commercialize innovations in the life science markets. Prior working at Debiopharm, Tanja was the Managing Partner of Innomedica Ltd, a leading European strategy consulting company in life sciences. She joined Debiopharm Innovation Fund S.A. in 2016.

Tom Gibbs

Tom Gibbs

Director, Debiopharm Innovation Fund S.A.

Dr Gibbs received his BSc in Applied Biology from the University of Wales Institute of Science and Technology, and earned his Ph.D. in Microbial Genetics at the University of Warwick. He has spent more than two decades in the commercialization of life science technologies, split equally between the pharmaceutical industry and scientific tool developers. He has been responsible for a wide range of activities including quality assurance, operations, late-stage product development and marketing, and increasingly business development. Dr. Gibbs has broad experience in both start-ups (Cytion, Covalys, Med Discovery) and more established companies (Delta Biotechnology, Molecular Devices, Debiopharm) in Europe and the USA. He joined Debiopharm International SA in 2012.

Debiopharm Innovation Fund S.A.

Campus 'après-demain'
Rue du Levant 146
1920 Martigny

Correspondance commerciale:
Forum "après-demain"
Chemin Messidor 5-7
Case postale 5911
1002 Lausanne
Switzerland

Tel. +41 (0)21 321 01 11
Fax +41 (0)21 321 01 69